BACKGROUND Limited data are available on the relative performances between different types of drug-eluting stents
The cumulative evidence from clinical trials and registries has suggested that PCI using a DES is an acceptable alternative to coronary artery bypass grafting (CABG) in selected patients with LMCA disease (4) (5) (6) (7) (8) . Recently, the primary results of 2 large randomized trials using second-generation DES have been reported; 1 study found PCI to be noninferior to CABG, whereas another study showed CABG to be superior to PCI (9, 10) . Although the disparate findings of the 2 trials lead to some uncertainty concerning the optimal revascularization strategy, both studies demonstrate how much PCI with a DES for LMCA revascularization has improved. However, until recently, data for the relative performance of the second-generation DES for the treatment of significant LMCA disease were limited. We therefore evaluated the comparative effectiveness and safety profiles of several second-generation DES for LMCA disease by using a pooled database from 3 large prospective clinical practice registries.
METHODS STUDY POPULATION, PROCEDURES, AND DATA
COLLECTION. The study population that underwent DES implantation for significant LMCA disease be- The study design and detailed entry criteria of each registry have been described previously (8, 11, 12) , and the key features are summarized in Online 
Lee et al. Table 1 and Online Table 3 .
Overall, there were no significant between-group differences with regard to age, sex, and several key clinical factors (diabetes, previous PCI, renal failure, peripheral vascular disease, ejection fraction, and clinical indication for PCI). There were, however, significant between-group differences in proportion of hyperlipidemia, family history of coronary artery disease, and history of heart failure or MI. Values are mean AE SD or n (%).
BP-BES ¼ biodegradable polymer biolimus-eluting stent(s); CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; CoCr-EES ¼ cobalt-chromium everolimus eluting stent(s); MI ¼ myocardial infarction; NSTEMI ¼ non-ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; PtCr-EES ¼ platinum-chromium everolimus-eluting stent(s); Re-ZES ¼ resolute zotarolimus-eluting stent(s); STEMI ¼ ST-segment elevation myocardial infarction. Table 4 ).
The adjusted hazard ratios for multiple DES comparisons after application of multiple treatment propensity score weighting are shown in Table 4 
DISCUSSION
In this pooled analysis of 3 multicenter, prospective registries, we did not find significant differences among rates of target-vessel failure at 3 years across different types of second-generation DES for LMCA disease, except that the use of PtCr-EES was associated with a higher risk of primary outcome than BP-BES. Overall, there were no substantial differences in the risks of patient-related outcomes of MACE and its individual components according to different types of DES. The incidence of stent thrombosis was considerably low (#1.0%) for all types of DES. Lee et al.
Comparison of DES for LM Coronary Artery PCI CI ¼ confidence interval; MACE ¼ major adverse cardiac events; TVR ¼ target-vessel revascularization; other abbreviations as in Table 1 . 
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Cumulative-incidence curves for target-vessel failure (A) and major adverse cardiac events (B). p values were calculated using the log-rank test. Target-vessel failure was defined as death from cardiac causes, target-vessel myocardial infarction, or target-vessel revascularization. Major adverse cardiac events were defined as the composite of all-cause death, myocardial infarction, or any revascularization. Abbreviations as in Figure 1 . CoCr-EES, which was associated with the lowest risk of stent thrombosis of all available DES in previous studies (24) . In contrast, the NOBLE study used a first-generation stent, with a thicker strut, the sirolimus-eluting stent (11%) or the BP-BES (Biomatrix Flex) (89%). There was a substantial difference in rate of definite stent thrombosis between the 2 trials (0.7% in the EXCEL and 3% in the NOBLE). In our study, definite or probable stent thromboses occurred in 3 patients (0.2%) treated with the Tables 1 and 3 .
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